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Smary Epirubicin (EPI), a doxorubicin analogue, is reported to have equal antitumour activity with lower
cardiac and systemic toxicity. Recently. the maximum tolerated dose of this drug has been revised upwards
with reported increased response rates in several malignancies. We initiated a phase II study of high-dose EPI
as initial treatment for patients with advanced non-small cell lung cancer (NSCLC) (stage III and IV). Between
May 1988 and November 1989, 25 patients were entered. The starting dose of EPI was 135 mg m2- with dose
attenuations and escalations of 15 mg m-2 based on mid-cycle evaluation of toxicity. Treatment was repeated
every 3 weeks. Nine partial responses (36%, 95% CI: 18-57.5%) and 11 patients with disease stabilisation
(44%) were observed. Median (range) time to progression was 19 (3-70) weeks. Median (range) survival is 32
(9-116+) weeks. There were no treatment related deaths. Major side effects were leukocytopenia WHO grade
III'IV (23% of courses) and mucositis WHO grade 11III (15% of courses). In two patients left ventricular
ejection fraction decreased > 15% compared to baseline values after a cumulative Epirubicin dose of
435 mg m2, and therefore went offstudy. In none of the patients clinical signs ofcongestive heart failure were
observed. We conclude from our data that high-dose EPI, contrary to previous negative studies using lower
doses of EPI, ranks amongst the most active regimens against advanced NSCLC. Toxicity of high-dose EPI is
moderate. Further evaluation of this compound in combination regimens is recommended.
Although several combination chemotherapy regimens can
produce response rates of more than 20% in unresectable
non small cell lung cancer (NSCLC), the impact on survival
is debatable and at best - albeit statistically significant -
marginal (Rapp et al., 1988; Williams et al., 1990). One
approach to improve these results is to explore the dose-
response relationship ofcytotoxic drugs. For anthracyclines a
number of cancer models (Frei et al., 1980; Razak et al.,
1972) and phase I II studies (Cortes et al., 1978; Yates et al.,
1982; Wheeler et al., 1982; Preisler et al., 1984; Carmo-
Pereira et al., 1986; Jones et al., 1987) are indicative for such
a relationship. The use of Doxorubicin (DOX) is limited by a
number of side effects, in particular a dose-related car-
diomyopathy. In order to overcome this problem, a series of
DOX analogues have been synthesised. One of these is 4'-
epidoxorubicin (Epirubicin (EPI)). Its spectrum of activity
was found to be virtually identical to that of DOX. though
the therapeutic index of EPI was more favourable, especially
in regard to cardiac toxicity (Torti et al.. 1986; Nielsen et al..
1990).
In the majority of phase I-II studies published. the dose of
EPI used was 75-90 mg m-2 on a 3 week schedule. However.
the favourable therapeutic index of EPI, led to a second
generation of phase I studies (Case et al., 1987; Case et al..
1988; Feld et al., 1988; Karp et al., 1989; Hickish et al., 1989;
Tjuljandin et al., 1990; Holdener et al., 1988; Walde et al..
1988), in order to define a range of higher doses of EPI that
could be safely administered as to deliver a higher dose-
intensity to non-hospitalised patients. The recommended dose
for further phase II studies has been established at
120-150mgm 2 every 3 weeks. Therefore, we initiated a
phase II study of high dose EPI, starting dose 135 mg m-,
as first line chemotherapy for patients with unresectable
NSCLC.
Mateei& and methods
Patients and staging
Between May 1988 and November 1989, 25 patients were
entered into this phase II trial. Eligibility criteria included
histological (or cytological) diagnosis of NSCLC; stage IV
disease or stage III disease unsuitable for resection or cura-
tive radiotherapy and no prior treatment with chemotherapy.
Additional eligibility requirements were: age between 19 and
69 years, performance status of s 2 on the Eastern Coopera-
tive Oncology Group scale; bidimensionally or unidimen-
sionally measurable lesions; at least 4 weeks since radiation
therapy (field compromising <25% of red bone marrow)
with measurable disease outside the radiation port, total
leukocyte counts ) 4,000 jl-', platelet count > 100,00011-',
serum creatinine less than 1.45mgdl-', serum bilirubin less
than 2.0 mg dl-', and a left ventricular ejection fraction
(LVEF) > 45% as measured by a multiple ECG-gated radio-
nucide study (MUGA-scan) (normal range: 55%-65%).
Life expectancy of at least 12 weeks and no history of
secondary malignancy (aside from localised basal or squa-
mous skin carcinoma) were specified. Patients with evaluable
disease only, brain metastases and those with a history of
myocardial infarction within the last 6 months or with arrhy-
thmias requiring permanent medication were excluded. Each
patient gave informed consent before entry into this study
according to local medical ethical committee regulations.
Before treatment, all patients underwent full staging proce-
dures including physical examination, chest x-ray. complete
blood cell counts, electrolytes, liver function chemistries.
serum creatinine, ECG, measurement of LVEF at rest and
tumour measurements. Additional studies were obtained to
document disease when indicated. Patients were staged accor-
ding to the criteria of the American Joint Committee for
Cancer Staging (1986) (Mountain, 1986).
The characteristics of the 25 patients entered into this trial
are summarised in Table I. The majority of the patients was
of the male sex with a median age of 58 years (range 43-69
years) and were in good clinical condition (median ECOG
PS 1). Two patients were pretreated with radiotherapy dir-
ected to the primary tumour and the mediastinum (total dose
60Gy for both patients) completed 12 and 9 weeks respec-
tively before entry into this study. All other patients had not
received any previous anti-neoplastic treatment.
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Tae I Patient characteristics
Characteristic
Median age (range)
Sex
Male
Female
ECOG performance score
0
Histology
Squamous
Adenocarcinoma
Large cell
Adenosquamous
Stage at diagnosis
IIIAT
III"
IV
Previous treatment
Radiotherapy
None
NVumber ofpatients
58 (43-69) years
I1
4
9
13
3
14
7
3
1
10
13
23
Treatment schedule and criteria for response and toxicitY
The starting dose of EPI was 135 mg m-. administered as an
IV bolus infusion. To control emesis. the administration of
dexamethasone (8 mg every 4 h for 36 h) was recommended.
Dose modifications were performed after the first cycle ac-
cording to the results of blood counts at midcycle (between
days 12 and 15. which is the expected nadir period as per the
new phase I studies): in case of leukocyte nadir > 2000 ilP'.
thrombocyte nadir ) 70.000 l-' and mucositis < grade I.
the next dose was increased by 15 mgm'. maintained at
the same dose level when leukocyte nadirs were between
1000 1-1 and 2000 L-1. and or thrombocyte nadirs between
40.000pl- and 70.000p1-'. and or mucositis - grade II.
The next dose was to be decreased with 15 mg m-' when the
leukocyte nadir < 1000;g1l-. thrombocyte nadir < 40.000
yl-1 or mucositis > grade 2. In case of incomplete bone
marrow recovery when the next course was due. therapy was
hold and blood counts were repeated weekly until complete
recovery of normal values. Then the dose was adjusted ac-
cording to results of mid-cycle evaluation.
Patients were treated until disease progression or a max-
imum cumulative dose of EPI of 900 mg m - or major tox-
icity, e.g. cardiac toxicity (see below). The whole treatment
was performed on an outpatient base.
Patients were considered evaluable for response if they
completed at least two courses of EPI with at least one
follow up (day 56). unless the patient had rapid disease
progression after one course. Complete response (CR) indi-
cated the documented disappearance of all signs and symp-
toms of detectable tumour and no development of new
lesions. A partial response (PR) was defined as a decrease of
at least 50% in the sum of the products of the two largest
perpendicular diameters of all measurable lesions and no
concomitant occurrence of new lesions. The situation in
which no change or decrease of less than 50% of the sum of
the products of the two largest perpendicular diameters of
measurable lesions occurred was defined as stable disease.
Disease progression was defined as a 25% increase in the
aforementioned lesions. Chest roentgenograms and/or com-
puter tomograms of all responding patients were subjected to
extra-mural review (N. van Zandwijk M.D., Netherlands
Cancer Institute, Amsterdam, The Netherlands).
Duration of response was from the first day of treatment
until the date of first observation of disease progression.
Time to progression was defined as the period from first day
of treatment to the date of first observation of disease pro-
gression. Survival, for which all patients were considered
evaluable, was dated from the first day of treatment until
death.
Toxicity was measured using the WHO grading system
(WHO, 1978) on days 12 and 14 of each course and at
retreatment. LVEF. using MUGA-scan. was measured prior
to treatment (baseline) and after three, five and six courses
of Epirubicin and every 2 months after discontinuation of
therapy. If the patient demonstrated an absolute drop of
) 15% of LVEF compared to baseline values. or less than
4500 (absolute value), the patient went off study and was
followed for survival.
Results
Toxicity
Twenty-four patients are evaluable for toxicity. owing to one
patient who died on day 14 of the first cycle due to rapidly
progressive brain metastases. Based on mid-cycle evaluation
of toxicity (see above). the dose of EPI had to be reduced
after the first cycle in one patient. due to WHO grade III
mucositis. In 17 patients the dose of EPI was escalated to
150 mg m-. In one of these patients it was necessary to
reduce the EPI dose with 30 mg m~- in the subsequent course
because of febrile neutropemna. Seven patients were treated
continuously with an EPI dose of 135 mg m-. A total
number of 107 courses. with a median of 5 (range 1-6). were
administered. The major toxicities are listed in Table II.
There were no treatment related deaths. WHO grade III
leukocytopenia was observed in 22% (eight patients) of
courses. while one patient experienced WHO grade IV leuko-
cyVtopenia. However. only one patient had to be hospitalised
because of neutropenia associated fever. In contrast, in one
patient (two courses) thrombocytopenia WHO grade III was
observed. Ten patients required red blood cell transfusions
during their course of treatment. All patients were sufficiently
recovered by day 21 to allow for a next course of EPI to be
initiated. Mucositis exceeding WHO grade I was observed in
16 (15%) courses, usually in conjuncture with leukocyto-
penia. Nausea and vomiting was not a significant problem. as
only 28% of courses was associated with WHO grade II
toxicity. which was usually of short duration, e.g. one day.
All patients had alopecia WHO grade < III. Five patients
had phlebitis of the infusion arm after administration of EPI
all after four or more courses. One of these patients therefore
went off study. Special attention was given to cardiac tox-
icity. monitored by serial MUGA scans. At entry. the median
LVEF was 66% (range 51-77%. n = 25). After three cour-
Table H Toxicity of high dose Epirubicin: median (range) nadirs of
hematological parameters and non hematological toxicities -~ ~~19
Dose
No. courses
Leukocytes
( x 1,000 JLL')
Thrombocytes
( X 1,00 JI-')
Hemoglobin
(grl')
Mucositis
WHO gr 0
gr I
grII
gr III
gr IV
Nausea vomiting
WHO gr 0
gr I
gr II
gr III
grIV
Infection
WHO gr 0
gr I
grII
gr III
gr IV
120mg m-
9
3.60
(1.10-4.20)
132
(89- 192)
112.5
(99- 131)
2
4
2
0
S
2
2
0
0
6
1
2
0
0
135 mgm -'
37
2.80
(1.20-7.10)
279
(87-637)
114.5
(69-135)
26
8
0
13
15
9
0
0
35
l
1
0
0
150mgm~-
61
2.80
(0.90-5.40)
184.5
(35-532)
107
(89- 132)
37
13
6
1
0
15
27
19
0
0
54
3
4
0
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ses, cumulative EPI dose 360-435 mg m2-, median LVEF
decreased to 61% (range 44-71%) (P<0.01, n = 18, Wilcox-
sons test for paired observations). After six courses (n = 13),
cumulative EPI dose 870-885 mg m-2, this figure further
decreased to 59% (range 45-68) (P<0.01 compared to
baseline values, but NS compared to LVEF after three
courses, Wilcoxsons test for paired observations). Two
patients had a drop of > 15% in LVEF compared to
baseline values. None of the patients entered into this study
had clinical signs of congestive heart failure. In one patient
LVEF decreased with 26% after a cumulative dose of
435 mg m2, subsequently this patient was taken off study.
However, 4 months later, a repeated MUGA scan revealed
that the LVEF had returned to baseline values. In the second
patient, LVEF decreased with 20% after three courses
(cumulative EPI dose 435 mg m-2). This patient died shortly
afterwards due to disease progression, without signs of con-
gestive heart failure. Other forms of toxicity were not
encountered.
Response and survival
All patients were assessable for response and response dura-
tion. Excluding the patient who experienced early death and
one patient who was lost to follow up after three months, 23
patients were assessable for survival. The exact date of death
is known for all remaining patients. Responses are listed in
Table III. After extramural review, one patient who was
considered non-responder, changed into a responder and vice
versa. There were no CR's, nine PR's (36%, 95% CI
18-57.5%). 11 patients (44%) had disease stabilisation, five
patients (16.7%) had PD after one (one patient) or two
courses. There were no significant differences in the response
between squamous (five PR's out of 14 patients) and non-
squamous (four PR's out of 11 patients) histology. Median
response duration (n = 9) was 20 weeks, range 9-70 weeks.
Median (range) time to progression for the whole group of
patients (n = 25) was 19 (2-70) weeks. Median survival (all
patients, n=23) was 32 (range 9-116+) weeks, with two
patients still alive 89 and 116 weeks after initiation of treat-
ment. Median survival was not different from patients ini-
tially classified as stage III and stage IV disease; 33 weeks vs
31.5 weeks. As can be expected, median survival of respon-
ding patients (44 weeks) was longer than for non-responding
patients (25 weeks).
Toxicity of so-called high dose EPI is manageable. Leukocy-
topenia, the dose limiting factor in the 'newer' phase I
studies, was the most frequently observed toxicity. Twenty-
three per cent of courses were associated with leukocytopenia
WHO grade > III. However, only one patient had to be
hospitalised because of leukocytopenia associated fever.
Mucositis was the second most frequent toxicity encountered;
in 15% of courses mucositis exceeding WHO grade I was
observed. Nausea and vomiting were seen in a minority of
the patients. No patient refused treatment because of this
toxicity. Alopecia was universal. Chronic toxicity, in partic-
ular cardiac toxicity, was uncommon. Only two patients had
a decrease in LVEF as measured by serial MUGA scan both
after a cumulative dose of 435 mg m-2. One of these patients
returned to baseline value after discontinuation of treatment.
However, neither these nor the other patients entered into
this study had signs of congestive heart failure. Sufficient
data now are available to conclude that cumulative EPI
doses up to 1,000 mg m-2 are infrequently associated with
cardiac toxicity (Nielsen et al., 1990, Rozencweig et al., 1984;
Shepherd et al., 1989). The only other form of chronic tox-
icity, phlebitis of the infusion arm, was seen in five patients
and led to discontinuation of treatment in one of them. In
three other studies (Hickish et al., 1989; Ferrazi et al., 1982;
Tabl m Response and survival
Response Nwnber ofpatients (%}
Number ofpatients evaluable for response: 25
Complete response 0 (0)
Partial response 9 (36)
Stable disease 11 (44)
Progressive disease 5 (20)
Number ofpatients evaluable for survival: 23
Median (range) survival (weeks):
All patients 32 (9-116+)
Stage III 31.5 (12-89+)
Stage IV 33 (9-116+)
Wils et al., 1984) this form of toxicity has been reported,
with an incidence between 3 and 17%.
To date, a large number of cytotoxic agents have been
tested against NSCLC in clinical trials. Of these, only a few
have demonstrated single agent response-rates ) 15%, which
might be considered as indicative for activity against NSCLC
(Kris et al., 1985). In 1986, Cerosimo and Hong reviewed the
single agent activity of EPI (Cerosimo & Hong, 1986).
Pooled data from eight different studies revealed a 9% res-
ponse rate in 211 patients. Doses of EPI used in these studies
ranged from 75 mg m-2 to 90 mg m-2. They concluded that,
'as a single agent, Epirubicin is inactive against NSCLC'.
However, the results of our study and others (Feld et al..
1988, Martoni et al., 1990, Wils et al., 1990) show that at
increased dose levels EPI may have activity in this malig-
nancy (Table IV). In a phase I study of EPI 55 mg m2
daily x 3 every 3 weeks Feld et al. (Feld et al., 1988)
observed a 21% response rate, all PR, in previously unt-
reated NSCLC patients. In a subsequently performed phase
II study by the same group (Feld et al., 1990) five out of 30
patients (17%) achieved a PR. Martoni et al. (Martoni et al.,
1990) treated 21 NSCLC patients with EPI doses ranging
from 120-165 mg m2 and obtained a response rate of 29%.
Finally Wils et al. (Wils et al., 1990), using the same schedule
as in our study, observed 6 PR (27%) out of 22 previously
untreated NSCLC patients. The results of our study - 9 PR
out of 25 evaluable patients - are thus in line with recently
published data. Despite the small number of patients in all
mentioned studies the response rates obtained support the
notion of a dose-response relationship for EPI in NSCLC. In
contrast to Feld et al. (Feld et al., 1990) who found a
significantly different response rate in non-squamous as
opposed to squamous histology (24% vs 6% respectively), in
this study, no such differences were observed. Median sur-
vival, albeit still rather poor - 32 weeks for all patients -, is
comparable to the results obtained with a variety of cisplatin
containing regimens. One way to improve this might be to
incorporate high dose EPI in combination regimens.
In summary, the principle finding of this study is that
evidence was found for the existence of a dose response
relationship for EPI in NSCLC. In spite of previously pub-
lished negative studies, the drug may have definite activity in
this malignancy. Further exploration of the efficacy of high
dose EPI in NSCLC seems to be justified based on the
number of responses seen in this and other studies.
Tabie IV Efficacy of high dose Epirubicin in NSCLC
Response (%)
Author No. patients CR PR Survival (weeks)
Feld (1988) 33 0 (0) 7 (21) 22.5
Feld (1990) 30 0 (0) 5 (17)
Martoni (1990) 21 0 (0) 6 (29) 25.7
Wils (1990) 22 0 (0) 6 (27) 21.4
Smit (this study) 25 0 (0) 9 (36) 32
Total 131 0 (0) 33 (25)408 E.F. SMIT et al.
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